UZH-Logo

Maintenance Infos

Browse by Creators - Zurich Open Repository and Archive

Navigate back| Up a level
Export as
Number of items: 16.

Wagner, N B; Weide, B; Reith, M; Tarnanidis, K; Kehrel, C; Lichtenberger, R; Pflugfelder, A; Herpel, E; Eubel, J; Ikenberg, K; Busch, C; Holland-Letz, T; Naeher, H; Garbe, C; Umansky, V; Enk, A; Utikal, J; Gebhardt, C (2015). Diminished levels of the soluble form of RAGE are related to poor survival in malignant melanoma. International Journal of Cancer, 137(11):2607-2617.

Schadendorf, D; Amonkar, M M; Milhem, M; Grotzinger, K; Demidov, L V; Rutkowski, P; Garbe, C; Dummer, R; Hassel, J C; Wolter, P; Mohr, P; Trefzer, U; Lefeuvre-Plesse, C; Rutten, A; Steven, N; Ullenhag, G; Sherman, L; Wu, F S; Patel, K; Casey, M; Robert, C (2014). Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study. Annals of Oncology, 25(3):700-706.

Flaherty, K T; Robert, C; Hersey, P; Nathan, P; Garbe, C; Milhem, M; Demidov, L V; Hassel, J C; Rutkowski, P; Mohr, P; Dummer, R; Trefzer, U; Larkin, J; Utikal, J; Dreno, B; Casey, M; Sherman, L J; Wu, F S; Schadendorf, D (2012). Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group. New England Journal of Medicine, 367(2):107-114.

Daud, A; Soon, C; Dummer, R; Eggermont, A M M; Hwu, W J; Grob, J J; Garbe, C; Hauschild, A (2012). Management of pegylated interferon alpha toxicity in adjuvant therapy of melanoma. Expert Opinion on Biological Therapy, 12(8):1087-1099.

Forschner, A; Schmidt, D; Garbe, C (2011). Hepatic hemangioma and hemochromatosis misdiagnosed by MRI as metastatic melanoma. Journal der Deutschen Dermatologischen Gesellschaft, 9(10):842-843.

Chapman, P B; Hauschild, A; Robert, C; Haanen, J B; Ascierto, P; Larkin, J; Dummer, R; Garbe, C; Testori, A; Maio, M; Hogg, D; Lorigan, P; Lebbe, C; Jouary, T; Schadendorf, D; Ribas, A; O'Day, S J; Sosman, J A; Kirkwood, J M; Eggermont, A M M; Dreno, B; Nolop, K; Li, J; Nelson, B; Hou, J; Lee, R J; Flaherty, K T; McArthur, A G (2011). Improved survival with vemurafenib in melanoma with BRAF V600E mutation. New England Journal of Medicine, 364(26):2507-2516.

Guggenheim, M; Giovanoli, P; Baumert, B G; Eigentler, T K; Garbe, C; Mangana, J; Dummer, R (2011). Melanoma. In: Dummer, R; Pittelkow, M; Iwatsuki, K; Green, A; Elwan, N M. Skin cancer - a world-wide perspective. Heidelberg, DE: Springer, 307-341.

Weide, B; Eigentler, T K; Pflugfelder, A; Leiter, U; Meier, F; Bauer, J; Schmidt, D; Radny, P; Pföhler, C; Garbe, C (2011). Survival after intratumoral interleukin-2 treatment of 72 melanoma patients and response upon the first chemotherapy during follow-up. Cancer Immunology, Immunotherapy, 60(4):487-493.

Garbe, C; Radny, P; Linse, R; Dummer, R; Gutzmer, R; Ulrich, J; Stadler, R; Weichenthal, M; Eigentler, T K; Ellwanger, U; Hauschild, A (2008). Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis. Annals of Oncology, 19(6):1195-1201.

Garbe, C; Schadendorf, D; Stolz, W; Volkenandt, M; Reinhold, U; Kortmann, R D; Kettelhack, C; Frerich, B; Keilholz, U; Dummer, R; Sebastian, G; Tilgen, W; Schuler, G; Mackensen, A; Kaufmann, R; Hauschild, A (2008). Short German guidelines: malignant melanoma. Journal der Deutschen Dermatologischen Gesellschaft, 6(Suppl ):S9-S14.

Garbe, C; Hauschild, A; Volkenandt, M; Schadendorf, D; Stolz, W; Reinhold, U; Kortmann, R D; Kettelhack, C; Frerich, B; Keilholz, U; Dummer, R; Sebastian, G; Tilgen, W; Schuler, G; Mackensen, A; Kaufmann, R (2008). Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting. Melanoma Research, 18(2):152-160.

Spieth, K; Kaufmann, R; Dummer, R; Garbe, C; Becker, J C; Hauschild, A; Tilgen, W; Ugurel, S; Beyeler, M; Bröcker, E B; Kaehler, K C; Pföhler, C; Gille, J; Leiter, U; Schadendorf, D (2008). Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the dermatologic cooperative oncology group (DeCOG). Annals of Oncology, 19(4):801-806.

Garbe, C; Hauschild, A; Volkenandt, M; Schadendorf, D; Stolz, W; Reinhold, U; Kortmann, R D; Kettelhack, C; Frerich, B; Keilholz, U; Dummer, R; Sebastian, G; Tilgen, W; Schuler, G; Mackensen, A; Kaufmann, R (2008). Evidence and interdisciplinary consensus-based German guidelines: surgical treatment and radiotherapy of melanoma. Melanoma Research, 18(1):61-67.

Weide, B; Carralot, J P; Reese, A; Scheel, B; Eigentler, T K; Hoerr, I; Rammensee, H G; Garbe, C; Pascolo, S (2008). Results of the first phase I/II clinical vaccination trial with direct injection of mRNA. Journal of Immunotherapy, 31(2):180-188.

Weide, B; Garbe, C; Rammensee, H G; Pascolo, S (2008). Plasmid DNA- and messenger RNA-based anti-cancer vaccination. Immunology Letters, 115(1):33-42.

Schnorf, M; Helfenstein, Ulrich; Blum, A; Ellwanger, U; Garbe, C; Burg, G; Dummer, R (2001). Erhebungen zur "prätherapeutischen Phase" des malignen Melanoms der Haut in der Schweiz in den Jahren 1996-1998. Praxis, 90(50):2193-2198.

This list was generated on Sun Jul 23 05:47:06 2017 CEST.